Breaking News:

Article ID: 694909

Article ID: 694730

Article ID: 694538

Research conducted in vitro shows two human antibodies made in response to vaccination against one hemorrhagic fever virus can disarm a related virus, for which there is currently no vaccine. The proof-of-principle finding identifies a common molecular chink in the two viruses’ armor that renders both vulnerable to the same antibodies. The results set the stage for a single vaccine and other antibody-based treatments that work against multiple viral “cousins” despite key differences in their genetic makeup. Such therapies can alleviate challenges posed by current lack of vaccines and prevent outbreaks of viral hemorrhagic fevers.

Article ID: 694529

The viruses that cause Ebola and Zika, daunting diseases that inspire concern at every outbreak, share a strong similarity in how they first infiltrate a host’s cells.

Article ID: 691734

An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.

Article ID: 689866

During the West African Ebola outbreak that began in 2013, an experimental biopharmaceutical drug called ZMappTM was a glimmer of hope in the midst of a health crisis. Now, scientists at Texas Biomedical Research Institute in San Antonio have been awarded a $2 million dollar contract by the makers of ZMapp, Mapp Biopharmaceutical, Inc., to further test this promising new therapeutic.

Article ID: 689655

The researchers will spend the next five years collecting data from Ebola and Lassa survivors to learn how they fought off the virus.

Article ID: 687718

Scientists at The Scripps Research Institute have discovered the workings of the first promising treatment for Marburg virus, a pathogen with the same pandemic potential as Ebola virus.

Article ID: 686837

Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks

Article ID: 685385

Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease. The results come from one of the most in-depth studies ever of blood samples from patients with Ebola.